Skip to content
drillr.ai
Sign up

PFE

PFIZER INC

NYSE · Healthcare · Drug Manufacturers - General · US

$27.60
−0.14%
Ask drillr

  • Aug 17, 2026, 09:30 UTC

    Ballentine Partners LLC reduced its stake in Pfizer Inc. by 18.2% during the second quarter of 2026, selling 18,852 shares, according to a Form 13F filing.

    Source:

  • Aug 17, 2026, 08:57 UTC

    Elevated Capital Advisors LLC reduced its stake in Pfizer Inc. by 53.2% during the second quarter, selling 24,066 shares and retaining 21,185 shares, as disclosed in a recent SEC filing.

    Source:

  • Aug 17, 2026, 03:35 UTC

    The United States Court of Appeals for the Third Circuit affirmed the district court's summary judgment in favor of Sun Pharmaceutical Industries and its subsidiaries in antitrust litigation brought by plaintiffs over a 2008 patent settlement with Pfizer concerning generic Lipitor.

    Source:

  • Aug 14, 2026, 15:11 UTC

    Pfizer agreed to pay $44 million to settle a class action lawsuit over its smoking-cessation drug Chantix, which was approved by the FDA in May 2006 and taken off the market in 2021.

    Source:

  • Aug 14, 2026, 05:00 UTC

    The European Medicines Agency validated the Marketing Authorization Application for Pfizer and Valneva's Lyme disease vaccine candidate PF-07307405 and will begin its assessment.

    Source:

  • Aug 11, 2026, 12:00 UTC

    Pfizer and Astellas launched a joint grant program for independent medical education on urothelial cancer, with a total budget of US$450,000 and individual grants of US$10,000 to US$150,000, targeting healthcare professionals outside the United States.

    Source:

  • Aug 6, 2026, 13:59 UTC

    Pfizer discontinued two obesity drug candidates, MET-224o and PF-07976016.

    Source:

  • Aug 6, 2026, 11:00 UTC

    Genevant and Arbutus received $950 million from Moderna in July 2026 under a $2.25 billion settlement, with additional $1.3 billion contingent on appeal resolution, and filed new international lawsuits against Pfizer and BioNTech covering 21 jurisdictions.

    Source:

  • Aug 5, 2026, 12:28 UTC

    On August 5, 2026, Akeso announced that its overseas partner Summit Therapeutics will initiate a global Phase II/III clinical study (HARMONi-GU1/AK112-3008) combining ivonescimab with enfortumab vedotin for first-line treatment of locally advanced or metastatic urothelial carcinoma, with Akeso leading the China portion and Summit leading overseas portions.

    Source:

  • Aug 5, 2026, 12:15 UTC

    Pfizer is seeking a new chief financial officer as Dave Denton is set to depart later this month.

    Source:

  • Aug 4, 2026, 14:38 UTC

    Pfizer expanded its cost reduction plan to $7 billion and aims for an additional $2.5 billion in savings by 2029.

    Source:

  • Aug 4, 2026, 10:57 UTC

    Pfizer plans to advance the Phase 3 program for berobenatide this year, which includes 10 studies targeting chronic weight management and obesity-related conditions.

    Source:

  • Jul 31, 2026, 19:00 UTC

    Pfizer enforced a court judgment freezing funds owed to air traffic control agencies in Poland and Romania over unpaid COVID-19 vaccine doses, after both countries refused deliveries in 2022 and appealed the ruling.

    Source:

  • Jul 31, 2026, 17:45 UTC

    Pfizer is pursuing a position in the obesity-drug market through its acquisition of Metsera and a broader GLP-1 pipeline.

    Source:

  • Jul 31, 2026, 05:23 UTC

    Pfizer and Eisai will begin joint promotional activities in Japan for the migraine treatment NURTEC ODT 75mg from September, aiming to strengthen information provision for proper use.

    Source:

  • Jul 30, 2026, 10:46 UTC

    Pfizer plans to initiate a pivotal study in 2026 evaluating Litfulo for the treatment of moderate alopecia areata.

    Source:

  • Jul 30, 2026, 10:45 UTC

    Pfizer announced positive topline Phase 3 results for LITFULO in patients with nonsegmental vitiligo.

    Source:

  • Jul 27, 2026, 11:04 UTC

    Pfizer announced that Amit Agarwal will resign as Chief Financial Officer, effective October 8, 2026.

    Source:

  • Jul 22, 2026, 20:30 UTC

    The U.S. FDA accepted for Priority Review Pfizer's supplemental New Drug Application for TALZENNA in combination with XTANDI for the treatment of metastatic castration-sensitive prostate cancer.

    Source:

  • Jul 16, 2026, 11:30 UTC

    Arbutus Biopharma and its licensee Genevant filed three international patent infringement lawsuits against Pfizer and BioNTech.

    Source:

  • Jul 10, 2026, 16:15 UTC

    The U.S. House Select Committee on the Chinese Communist Party launched a bipartisan investigation into five major American pharmaceutical companies over clinical trials conducted in China, including at hospitals linked to the People's Liberation Army and in Xinjiang province, sending letters demanding records by July 17.

    Source:

  • Jul 10, 2026, 15:23 UTC

    The U.S. FDA approved PADCEV plus Keytruda as neoadjuvant and adjuvant treatment for muscle-invasive bladder cancer.

    Source:

  • Jul 9, 2026, 23:59 UTC

    Pfizer and co-defendants reached a global settlement in principle with plaintiffs in the Depo-Provera multidistrict litigation on June 15, 2026.

    Source:

  • Jul 2, 2026, 15:00 UTC

    Pfizer obtained a Belgian court ruling leading to garnishment of funds destined for Romania via ROMATSA.

    Source:

  • Jun 30, 2026, 21:52 UTC

    Nike appointed Dave Denton, formerly CFO of Pfizer, as its new Finance Chief.

    Source:

  • Jun 19, 2026, 15:25 UTC

    Pfizer's CFO Dave Denton announced his exit from the company.

    Source:
← PreviousPage 2Next →